George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-8. doi:10.1038/nature07397
Stanley SA, Grant SS, Kawate T, et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol. 2012;7(8):1377-84. doi:10.1021/cb300151m
Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3(3):350-62. doi:10.1158/2159-8290.CD-12-0470
Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013;110(20):8188-93. doi:10.1073/pnas.1300252110
Ottoboni L, Frohlich IY, Lee M, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013;81(22):1891-9. doi:10.1212/01.wnl.0000436612.66328.8a
Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014;20(3):251-4. doi:10.1038/nm.3480
Garraway LA. A Notch for noncoding RNA in melanoma. N Engl J Med. 2014;370(20):1950-1. doi:10.1056/NEJMcibr1402173
Bellmunt J, Selvarajah S, Rodig S, et al. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014;9(8):e103325. doi:10.1371/journal.pone.0103325
Theurillat JPP, Udeshi ND, Errington WJ, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346(6205):85-9. doi:10.1126/science.1250255
Leiserson MDM, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106-14. doi:10.1038/ng.3168